Taken together, reduced CCL3 levels in PBMCs a reflects a systemic immune dysregulation, reduced immune cell recruitment to the tumor, potentially diminishing the efficacy of the anti-tumor activity against CRC cells promoting tumor growth and metastasis [35]. This evidence concerns the gene CCL3 and colorectal carcinoma.